FDA Advisory Committee Recommends Accelerated Approval of JNJ's Investigational Multi-Drug Resistant Tuberculosis Treatment Bedaquiline
This week while attending the Partnering for Cures meeting in New York (http://www.
Surprisingly, little mention of this panel decision was made at the meeting in New York, which is unfortunate because the background story behind it illustrates many of the aspects discussed at the meeting. For example Public Private Partnerships (J&J and TB Alliance), PDUFA, Philanthropy etc... Maybe next year it will be highlighted. While not likely to be a very profitable drug it will provide good visibility for J&J and help to bolster the image of a company and an industry that has taken a lot of setbacks in recent years.
Let's hope it encourages other companies to collaborate to discover drugs for this disease that are faster acting and less toxic than current treatments and that it does not take another 40 years to get there.
Sean Ekins Ph.D, D.Sc.
VP, Science. CDD.
This blog is authored by members of the CDD Vault community. CDD Vault is a hosted drug discovery informatics platform that securely manages both private and external biological and chemical data. It provides core functionality including chemical registration, structure activity relationship, chemical inventory, and electronic lab notebook capabilities!
CDD Vault: Drug Discovery Informatics your whole project team will embrace!
Other posts you might be interested in
View All Posts
CDD Blog
5 min
July 22, 2025
Drug Discovery Industry Roundup with Barry Bunin — July 22, 2025
Read More
Events
4 min
July 17, 2025
Recap Of The Collaborative Drug Discovery's Inaugural Canadian User Group Meeting
Read More
CDD Vault Updates
2 min
July 10, 2025
CDD Vault Update (July 2025): Custom Axis Scaling, AUC Fold Change, Copy Reactions and Stoichiometry Tables, and Sample Tracking Improvements for the ELN
Read More